This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
SEE YOU NEXT YEAR: May 7-10, 2023 | In-Person + Digital
San Diego, CA, USA

Christian Marsolais, PhD
Senior Vice President and Chief Medical Officer at Theratechnologies Inc


Dr. Christian Marsolais has been Senior Vice President and Chief Medical Officer since June 2016. He joined Theratechnologies in 2007. He brings more than 30 years of experience in the research, development and commercialization of new drugs. He started his career working for global pharmaceutical companies, including Sandoz (now Novartis), Biochem and Pfizer. Prior to joining Theratechnologies, he was part of the global oncology team at Pfizer. Dr. Marsolais led the medical team which was central to the approval of Egrifta® by the Food and Drug Administration in the United States. He was also instrumental in the efforts that led to the acquisition of the commercial rights to Trogarzo® in the United States and Europe and its subsequent approval. He was also closely involved in the acquisition of Katana Biopharma Inc., which discovered the SORT1+ Technology™ Platform. Under Dr Marsolais’ direction, this platform moved rapidly through preclinical development and into the clinical setting with the initiation of the FIH study with the lead candidate, a peptide drug conjugate (PDC), TH1902. In addition, he is responsible for the development of tesamorelin for the potential treatment of NASH. Dr. Marsolais holds a Ph.D. in biochemistry from the Université de Montréal.

Agenda Sessions

  • SORT1+ TechnologyTM Platform & Novel Peptide Drug Conjugates (PDC’s) Targeting Sortilin (SORT1) Positive Cancers